Literature DB >> 26954802

Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?

Pinaki Dutta, Márta Korbonits, Naresh Sachdeva, Prakamya Gupta, Anand Srinivasan, Jagtar Singh Devgun, Ankur Bajaj, Kanchan Kumar Mukherjee1.   

Abstract

BACKGROUND: Growth hormone (GH) levels following oral glucose tolerance test (OGTT) at 12 weeks or later after surgery have been accepted as the most reliable parameter for defining remission and/or cure in patients with acromegaly. However, the role of random GH in predicting remission in the immediate postoperative period using modern criteria is not known. This study was undertaken to evaluate the role of random GH levels in first 5 postoperative days as an early predictive tool for long-term remission of patients with acromegaly following transsphenoidal pituitary surgery (TSS). PATIENTS AND METHODS: Seventy-five consecutive acromegaly patients with at least three postoperative OGTT values at 3, 6, and 12 months of follow-up were included in the study. GH levels were measured just before surgery, in the immediate postoperative period, at 6 h and on day 1 to day 5 after surgery. Remission was defined as normal age-specific insulin-like growth factor-1 and either basal fasting GH <1 ng/ml or a nadir GH following OGTT <0 .4 ng/ml at 3 months of surgery.
RESULTS: Of the 75 patients with acromegaly who underwent TSS, long-term remission was achieved in 42 (56%) patients. GH values ≤1.55 ng/ml at 6 h of surgery showed the highest predictive power for long-term remission, with a sensitivity of 81.2% and a specificity of 83.3%. The duration of disease and tumor volume had no effect on the 6 h GH value-related prediction of cure.
CONCLUSION: Early postoperative GH values may be used to predict long-term cure. A value of ≤1.5 ng/ml at 6 h following surgery may predict long-term cure in two-thirds of the patients with acromegaly who undergo TSS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26954802     DOI: 10.4103/0028-3886.177622

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  5 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

2.  Early postoperative prediction of both disease remission and long-term disease control in acromegaly using the oral glucose tolerance test.

Authors:  Kiyohiko Sakata; Yui Nagata; Nobuyuki Takeshige; Jin Kikuchi; Masato Shikata; Kenji Ashida; Masatoshi Nomura; Motohiro Morioka
Journal:  Hormones (Athens)       Date:  2021-03-18       Impact factor: 2.885

3.  Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.

Authors:  Tyler Cardinal; Casey Collet; Michelle Wedemeyer; Peter A Singer; Martin Weiss; Gabriel Zada; John D Carmichael
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-18       Impact factor: 5.555

4.  Machine learning-based clinical outcome prediction in surgery for acromegaly.

Authors:  Olivier Zanier; Matteo Zoli; Victor E Staartjes; Federica Guaraldi; Sofia Asioli; Arianna Rustici; Valentino Marino Picciola; Ernesto Pasquini; Marco Faustini-Fustini; Zoran Erlic; Luca Regli; Diego Mazzatenta; Carlo Serra
Journal:  Endocrine       Date:  2021-10-12       Impact factor: 3.633

5.  First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence.

Authors:  V Cambria; G Beccuti; N Prencipe; F Penner; V Gasco; F Gatti; M Romanisio; M Caputo; E Ghigo; F Zenga; S Grottoli
Journal:  J Endocrinol Invest       Date:  2021-04-10       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.